Looks like a mass scheduling is on the way.
[Federal Register: October 20, 2006 (Volume 71, Number 203)]
[Notices]
[Page 62017-62018]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20oc06-90]
[[Page 62017]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-274N]
Solicitation of Information on the Use of Phenethylamine-Related
Compounds
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice, solicitation of information.
-----------------------------------------------------------------------
SUMMARY: The DEA is soliciting information on substances that are
related in chemical structure to phenethylamine (see supplementary
information). The Controlled Substances Act (CSA), Title 21 of the
United States Code (U.S.C.) Sec. 812(c) schedule I (Title 21 of the
Code of Federal Regulations (CFR) Sec. 1308.11(d)), lists certain
phenethylamines as schedule I controlled substances. Some
phenethylamines that are not controlled under the CSA produce central
nervous system effects that are similar to phenethylamines that are
controlled under the CSA. DEA is requesting information to help
determine the impact on business if these substances were to be placed
under control in the CSA.
DATES: Written comments must be postmarked, and electronic comments
must be sent, on or before December 19, 2006.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-274N'' on all written and electronic correspondence.
Written comments being sent via regular mail should be sent to the
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL. Written comments sent via express
mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
VA 22301. Comments may be directly sent to DEA electronically by
sending an electronic message to dea.diversion.policy@usdoj.gov (mailto:dea.diversion.policy@usdoj.gov).
Comments may also be sent electronically through http://www.regulations.gov (http://www.regulations.gov)
using the electronic comment form provided on that
site. An electronic copy of this document is also available at the
http://www.regulations.gov (http://www.regulations.gov) Web site. DEA will accept attachments to
electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel
file formats only. DEA will not accept any file format other than those
specifically listed here.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537; Telephone: (202) 307-
7183.
SUPPLEMENTARY INFORMATION: Tryptamine is a compound in which the
chemical structure can be described as indole substituted at the three
position with an 2-aminoethyl chain. Although tryptamine itself is not
a controlled substance, its chemical structure constitutes the skeletal
makeup of tryptamines listed in Schedule I of the CSA, which are
classified as hallucinogenic substances.
Tryptamine is sometimes substituted on the indole ring or the 2-
aminoethyl chain or both with various substituents. Title 21 CFR
1308.11(d) lists specific substituted tryptamines in Schedule I. Also
included in Schedule I are the salts, isomers, and salts of isomers of
the listed tryptamines. The term isomer, as used in this section, means
the optical, geometric, and positional isomers.
Individuals have published detailed methods of synthesis for
substituted tryptamines and have reported pharmacological effects based
on user experiences. Law enforcement personnel encounter such
tryptamines, but because they are substituted differently than those
listed or described in the CSA, they are not subject to direct control
in Schedule I. However, some of these substances can be treated as
Schedule I controlled substance analogues if intended for human
consumption (21 U.S.C. 802(32); Sec. 813).
DEA is soliciting information on (1) The commercial uses for
tryptamines, (2) activities involving research and development, (3)
tryptamines as intermediates or analytical standards, (4) import and
domestic sources for tryptamines, and (5) any planned or anticipated
uses for tryptamines. DEA invites interested persons to provide any
information on the uses of tryptamines in industry, academia, research
and development, or other applications. Both quantitative and
qualitative information is sought.
Although information is requested for all tryptamine substances
regardless of substitutions, DEA is particularly interested in
tryptamines that meet one
[[Page 44315]]
or more of the following conditions: (a) Has a secondary or tertiary
amine formed by the substitution on the nitrogen atom of the 2-
aminoethyl chain by various alkyl groups, whether in chain or ring form
(for example, N-alkyltryptamine, N,N-dialkyltryptamine, N,N-
tetramethylenetryptamine), (b) has an alkyl substitution on the alpha
position of the 2-aminoethyl chain, and/or (c) has substituents on the
indole ring system, including, but not restricted to, various alkyl
chains, halogens, hydroxyl, alkoxy, acetyl, or alkylthio groups, at one
or more positions except the one (indole nitrogen) position. DEA is
especially interested in learning of the uses of the following
tryptamines.
2-alpha-dimethyltryptamine
4-hydroxy-N,N-diisopropyltryptamine
4-hydroxy-N,N-dipropyltryptamine
4-hydroxy-N,N-tetramethylenetryptamine
4-hydroxy-N-isopropyl-N-methyltryptamine
4-hydroxy-N-methyl-N-propyltryptamine
5,6-dimethoxy-N-isopropyl-N-methyltryptamine
5-methoxy-alpha,N-dimethyltryptamine
5-methoxy-alpha-methyltryptamine
5-methoxy-N,N-dimethyl-2-methyltryptamine
5-methoxy-N,N-dimethyltryptamine
5-methoxy-N,N-tetramethylenetryptamine
5-methoxy-N-methyltryptamine
6-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline
7-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline
9,10-didehydro-6-allyl-N,N-diethylergoline-8-beta-carboxamide
9,10-didehydro-6-propyl-N,N-diethylergoline-8-beta-carboxamide
9,10-didehydro-N,N,6-triethylergoline-8-beta-carboxamide
alpha,N-dimethyltryptamine
N,N-dibutyltryptamine
N,N-dibutyl-4-hydroxytryptamine
N,N-diethyl-2-methyltryptamine
4-hydroxy-N,N-diethyltryptamine
N,N-diethyl-5-methoxytryptamine
N,N-diisopropyl-4,5-methylenedioxytryptamine
N,N-diisopropyl-5,6-methylenedioxytryptamine
N,N-diisopropyltryptamine
N,N-dimethyl-2-methyltryptamine
N,N-dimethyl-4,5-methylenedioxytryptamine
N,N-dimethyl-4-hydroxytryptamine
N,N-dimethyl-5,6-methylenedioxytryptamine
N,N-dimethyl-5-methylthiotryptamine
N,N-dipropyltryptamine
N,N-tetramethylenetryptamine
N-butyl-N-methyltryptamine
N-ethyl-4-hydroxy-N-methyltryptamine
N-ethyl-N-isopropyltryptamine
N-ethyltryptamine
4-methoxy-N-methyl-N-isopropyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamine
N-isopropyl-N-methyl-5,6-methylenedioxytryptamine
N-isopropyl-N-methyltryptamine
N-methyltryptamine
4-acetoxy-N-methyl-N-isopropyltryptamine
4-acetoxy-N,N-diisopropyltryptamine
4-acetoxy-N,N-dipropyltryptamine
4-acetoxy-N,N-diethyltryptamine
5-methoxy-N,N-diallyltryptamine
5-methoxy-N-monoallyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamin
N-methyl-N-isopropyltryptamine
4-hydroxy-N,N-diethyltryptamine
5-methoxy-N,N-diethyltryptamine
Such information may be submitted to the Drug and Chemical
Evaluation Section and is requested by October 3, 2006. Information
designated as confidential or proprietary will be treated accordingly.
Confidential business information is protected from disclosure under
Exemption 4 of the Freedom of Information Act, 5 U.S.C. 552(b)(4)(FOIA)
and the Department of Justice procedures set forth in 28 CFR 16.8.
Dated: July 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.
[FR Doc. E6-12599 Filed 8-3-06; 8:45 am]
BILLING CODE 4410-09-P
:cry: :cry: :cry: ----------sal
Weird, some of those things are not even psychoactive. For example, in TiHKAL n-methyl-tryptamine is non-active. :roll: